Name of the Procedure:

Injection, elotuzumab, 1 mg (HCPCS Code: J9176)

Summary

Elotuzumab is a medication administered through an injection. It is typically used in the treatment of certain types of cancer, specifically multiple myeloma. The procedure involves injecting a small dose of this medication into the patient's bloodstream.

Purpose

The procedure aims to treat multiple myeloma, a type of blood cancer. Elotuzumab is designed to target and kill specific cancer cells, helping to control the progression of the disease and potentially lead to remission.

Indications

• Multiple myeloma that has not responded to or has relapsed after other treatments.
• Patients suited for immunotherapy where elotuzumab is included as part of a treatment regimen.
• Specific patient criteria may include previous treatment history and overall health status.

Preparation

• Patients may be advised to fast for a few hours before the injection.
• Pre-procedural tests like blood counts, kidney function tests, and other lab assessments may be required.
• Patients should inform their healthcare provider of any other medications they are taking, as some may need to be adjusted.

Procedure Description

1. The patient is seated or lying comfortably.
2. A healthcare professional cleans the injection site with an antiseptic.
3. Elotuzumab is prepared in a controlled dosage (1 mg) and injected intravenously.
4. The injection is administered slowly to monitor patient response.
5. After the injection, the site may be observed for any immediate adverse reactions.

This procedure uses sterile injection equipment and careful monitoring, possibly with mild sedation if the patient experiences anxiety or discomfort.

Duration

The procedure typically takes around 15 to 30 minutes, including preparation and post-injection observation.

Setting

The injection is usually administered in an outpatient clinic, hospital, or specialized oncology treatment center.

Personnel

• Oncologist or specialized physician
• Registered nurse or trained medical professional
• Support staff for monitoring and assistance

Risks and Complications

• Common risks: Injection site reactions (e.g., redness, swelling), mild fever, or fatigue.
• Rare risks: Severe allergic reactions, infections, or immune system complications.
• Possible complications include infusion reactions, manageable with immediate medical intervention.

Benefits

• Elotuzumab may help reduce or eliminate multiple myeloma cells, contributing to disease control or remission.
• Improvement in quality of life and prolonged survival rates may be realized within weeks to months.

Recovery

• Patients are typically observed for a short period post-injection for any immediate adverse effects.
• Normal activities can often be resumed the same day unless otherwise advised.
• Follow-up appointments are necessary to monitor the disease and adjust treatment as needed.

Alternatives

• Other treatment options include other chemotherapy drugs, stem cell transplants, or alternative immunotherapy agents.
• Pros: Some alternatives may offer fewer side effects or different mechanisms of action.
• Cons: Alternatives may not be as effective for specific patient profiles or may entail different risk factors.

Patient Experience

• During the procedure, patients might feel a slight prick and mild discomfort at the injection site.
• Post-injection, patients may experience mild side effects like fatigue or fever, which are typically managed with over-the-counter medications.
• Pain management includes applying cold compresses to the injection site and using prescribed pain relief if necessary.